La vendita allo scoperto per SPDR S&P Kensho New Economies Composite ETF dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di SPDR S&P Kensho New Economies Composite ETF. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

SPDR S&P Kensho New Economies Composite ETF (ARCA:KOMP), Report sulle vendite allo scoperto

Technology

Industrials

Healthcare

Financial Services

Communication Services

Consumer Cyclical

Utilities

Basic Materials

Energy

Other

Consumer Defensive

Real Estate

Under normal market conditions, the fund generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index is designed to capture companies whose products and services are driving innovation and transforming the global economy through the use of existing and emerging technologies, and rapid developments in robotics, automation, artificial intelligence, connectedness and processing power. The fund is non-diversified.

Oceaneering International Inc

Teledyne Technologies Inc

Parsons Corporation Com

Bruker Corp.

Coinbase Global, Inc.

Kratos Defense & Security Solutions, Inc.

Lockheed Martin Corp

Leidos Holdings, Inc.

Paysafe Ltd

Aerovironment Inc

SPDR S&P Kensho New Economies Composite ETF

Scotiabank analyst Nick Altmann maintains JFrog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) with a Sector Perform and raises the price target from $25 to $30.

News

Price Target

Analyst Ratings

FROG

Scotiabank Maintains Sector Perform on JFrog, Raises Price Target to $30

WIIM

UEIC

Universal Electronics shares are trading higher after the company issued Q4 revenue guidance above estimates. Also, Rosenblatt upgraded the stock from Neutral to Buy.

Piper Sandler analyst Brent Bracelin maintains OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) with a Overweight and raises the price target from $34 to $37.

Piper Sandler Maintains Overweight on OneStream, Raises Price Target to $37

Scotiabank analyst Phil Hardie maintains IGM Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IGM#TSX">IGM</a>) with a Sector Perform and raises the price target from C$53 to C$56.

TSX:IGM

Scotiabank Maintains Sector Perform on IGM Financial, Raises Price Target to C$56

APYX

Apyx Medical shares are trading lower after the company cut its FY24 and FY25 revenue guidance.

VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>, Euronext Amsterdam: VEON))), a global digital operator, is pleased to announce that a VEON delegation led by VEON Chairman and Founder Augie Fabela, VEON Group CEO Kaan Terzioglu and Jazz CEO Aamir Ibrahim visited Prime Minister of Pakistan Shehbaz Sharif today in Islamabad, to discuss the advancement of the country's digital landscape.
The Prime Minister commended Jazz's role in driving digital transformation and fostering economic empowerment through technology. During the meeting, the VEON delegation provided a comprehensive overview of VEON's substantial investments in Pakistan's digital infrastructure through Jazz and Mobilink Bank, serving more than 70 million mobile users, more than 63 million monthly active users (MAUs) across its digital services such as JazzCash, Tamasha, Simosa, and thousands of enterprise clients from small and medium businesses to the country's largest national and multinational conglomerates, supporting the digitalization of Pakistan's economy.
The delegation also met with Finance Minister Muhammad Aurangzeb; Minister of State for IT &amp; Telecommunications Shaza Fatima Khawaja; Jameel Ahmed, the Governor of the State Bank of Pakistan; Pakistan Telecommunications Authority Chairman Major General (R) Hafeez-Ur-Rehman.

Global

VEON

VEON Group Reaffirms Commitment To Strengthen Pakistan's Digital Infrastructure In Meeting With Prime Minister Shehbaz Sharif

Piper Sandler analyst Anna Andreeva maintains Warby Parker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) with a Overweight and raises the price target from $18 to $22.

WRBY

Piper Sandler Maintains Overweight on Warby Parker, Raises Price Target to $22

Benchmark analyst Daniel Kurnos maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Buy and raises the price target from $180 to $200.

EXPE

Benchmark Maintains Buy on Expedia Group, Raises Price Target to $200

PBYI

Puma Biotechnology shares are trading higher after the company reported better-than-expected Q3 financial results and raised the lower end of its Q24 revenue guidance.

Piper Sandler analyst Patrick Moley maintains Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) with a Overweight and raises the price target from $30 to $32.

Piper Sandler Maintains Overweight on Marex Group, Raises Price Target to $32

On Friday, Amneal Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) reported third-quarter adjusted EPS of $0.16, down from $0.19 a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $0.14</a>.
The company reported sales of $702.47 million, up 13% year-over-year, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41838696/amneal-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">consensus of $696.80 million</a>.
Generic net revenue increased by 9% to $427.35 million, driven by the strong performance of new product launches and biosimilars.
Specialty net revenue increased 19% to $115.64 million, driven by promoted products in neurology and endocrinology, including the recent launches of CREXONT&nbsp;and ONGENTYS&nbsp;for Parkinson&#8217;s disease.
AvKARE&#8217;s net revenue increased by 21% to $159.49 million, driven by growth across its distribution and government-label sales channels.
Adjusted EBITDA in the third quarter of 2024 was $158 million, an increase of 2% compared to the third quarter of 2023, reflective of strong revenue performance and higher gross margins, partially offset by a $20 million research and development milestone payment associated with the company&#8217;s exclusive license of Omalizumab during the third quarter of 2024.
&#8220;Q3 was an excellent quarter where we continued to drive strong financial results across our diversified business and we announced three strategic actions to solidify our long-term growth:
<ol>
<li>We launched CREXONT for the treatment of Parkinson&#8217;s disease.</li>
<li>We announced our collaboration with Metsera, Inc. to leverage Amneal&#8217;s expertise and supply next-generation medicines for obesity and metabolic diseases.</li>
<li>We expanded our deep pipeline by in-licensing a new high-value biosimilar,&#8221; said Chirag and Chintu Patel, Co-CEOs.</li>
</ol>
Guidance: Amneal has reaffirmed its 2024 revenue guidance of $2.7 billion—$2.8 billion and adjusted EPS of $0.57-$0.63, versus the consensus of $2.76 billion and $0.60, respectively.
The company expects 2024 adjusted EBITDA of $610 million—$630 million, operating cash flow&nbsp;of $280 million—$320 million and capital expenditures of $60 million—$70 million.
Price Action: At last check on Friday, AMRX stock down up 4.88% to $8.19 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/forex/24/11/41839609/asia-markets-mixed-europe-crude-oil-gold-and-dollar-cool-off-global-markets-today-while-us-slept" target="_blank" rel="noreferrer noopener">Asia Markets Mixed, Europe, Crude Oil, Gold, And Dollar Cool Off &#8211; Global Markets Today While US Slept</a></li>
</ul>

Earnings

Guidance

Health Care

Movers

General

AMRX

Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts

Clover Leaf Capital Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLOE#OTC">CLOE</a>) (the "Company" or "Clover Leaf"), announced today that Clover Leaf and Kustom Entertainment, Inc. ("Kustom Entertainment") have mutually agreed to terminate their previously announced Agreement and Plan of Merger (the "Merger Agreement"), effective as of&nbsp;November 7, 2024&nbsp;by entering into a mutual termination and release agreement (the "Termination and Release Agreement") among Clover Leaf,&nbsp;CL Merger Sub, Inc., Yntegra Capital Investments LLC, Kustom Entertainment and Digital Ally, Inc.&nbsp;
The Merger Agreement was dated as of June 1, 2023, as amended on June 24, 2024 and on September 3, 2024. The Termination and Release Agreement terminates the Merger Agreement, which will be described in a Current Report on Form 8-K to be filed by Clover Leaf.
In view of the termination of the Merger Agreement, Clover Leaf also announced its decision to cancel its special meeting originally scheduled for November 8, 2024 and the withdrawal from consideration by the stockholders of the Company the proposals set forth in the Company's definitive proxy statement, as amended, filed with the Securities and Exchange Commission (the "SEC") on July 31, 2024 (the "Definitive Proxy Statement").
As a result of the termination of the Merger Agreement, the Company's Board of Directors has determined to liquidate the Company and expects that it will redeem all of its outstanding shares of Class A common stock sold as part of the units in the Company's initial public offering. The Company expects to announce additional information on such redemption in the coming days.

Contracts

CLOE

Clover Leaf Capital Corp. Announces Termination Of Merger Agreement With Kustom Entertainment, Inc., Cancellation Of Special Meeting Originally Scheduled For November 8, 2024 And Its Intention To Liquidate And Redeem All Of Its Outstanding Shares Of Class A Common Stock Sold As Part Of The Units In The Company's Initial Public Offering

ULBI

Ultralife shares are trading lower after the company reported worse-than-expected Q3 financial results.

STKS

The One Group Hospitality shares are trading lower after the company reported worse-than-expected Q3 financial results.

Piper Sandler analyst Charles Neivert maintains Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) with a Overweight and lowers the price target from $62 to $60.

Piper Sandler Maintains Overweight on Dow, Lowers Price Target to $60

Citigroup analyst Peter Christiansen upgrades Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) from Neutral to Buy and raises the price target from $56 to $87.

Upgrades

UPST

Citigroup Upgrades Upstart Hldgs to Buy, Raises Price Target to $87

TNYA

Tenaya Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results. Chardan Capital maintained a Buy rating on the stock.

Envoy Medical&#xAE;, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announces that the European Patent Office has granted the Company Patent No. 3858425, titled," Implantable Modular Cochlear Implant System with Communication System and Network."
The patent relates to a modular cochlear implant system configured to receive input signals from an implantable source and a wireless receiving device and output a stimulation signal based on the received input signals and a programmable mixing ratio representative of the relative contributions of the input signals to the stimulation signal.&nbsp;

Envoy Medical, Inc. - Class A Common Stock

COCH

Envoy Medical Receives European Patent No. 3858425, Titled, "Implantable Modular Cochlear Implant System With Communication System And Network"

Piper Sandler analyst Charles Neivert maintains CF Industries Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) with a Underweight and raises the price target from $77 to $79.

Piper Sandler Maintains Underweight on CF Industries Holdings, Raises Price Target to $79

CTMX

CytomX Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.

Comments

SPDR S&P Kensho New Economies Composite ETF

Vendite allo scoperto

SPDR S&P Kensho New Economies Composite ETF (ARCA:KOMP), Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO